JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB274943

Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line

Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IRF9 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein Frameshift = 98%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

別名を表示する

IFN-alpha-responsive transcription factor subunit, IRF9_HUMAN, ISGF-3, ISGF-3 gamma, ISGF3 p48 subunit, ISGF3G, Interferon regulatory factor 9, Interferon-stimulated gene factor 3 gamma, OTTHUMP00000164692, OTTHUMP00000164693, P48, Transcriptional regulator ISGF3 subunit gamma, interferon stimulated transcription factor 3, interferon-stimulated transcription factor 3, gamma 48kDa

1 Images
Next Generation Sequencing - Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line (AB274943)
  • NGS

Lab

Next Generation Sequencing - Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line (AB274943)

1 bp insertion after Met102 of the WT protein

Key facts

細胞タイプ

MCF7

生物種

Human

組織

Breast

製品の状態

Liquid

form

ノックアウト検証方法

Next Generation Sequencing

ノックアウト変異

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein Frameshift = 98%

疾病

Adenocarcinoma

製品の詳細

Recommended control: Human wild-type MCF7 cell line (ab271144). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

製品内容

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab274943-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line kit component", "number":"AB274943-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab274943-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human wild-type MCF7 cell line kit component", "number":"AB274943-CMP02", "productcode":"" }, { "size":"1 x 1000000 Cells/vial", "name":"Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line kit component", "number":"AB274943-CMP01", "productcode":"" } ] } } }

出荷温度及び保存条件

遺伝子名
IRF9
遺伝子編集のタイプ
Knockout
遺伝子編集の方法
CRISPR technology
ノックアウト検証方法
Next Generation Sequencing
接合型
Homozygous
出荷温度
Dry Ice
短期保存期間
1-2 weeks
短期保存温度
-196°C
長期保存温度
-196°C

取り扱い方法

初回取り扱いガイドライン

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

継代培養ガイドライン
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
培養培地

MEM + 10% FBS + 0.01 mg/ml bovine insulin

凍結保存培地

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Interferon regulatory factor 9 (IRF-9) also known as ISGF3-γ is a critical component in the transcriptional regulation of interferon-stimulated genes. This protein with a mass of approximately 48 kDa serves as an important mediator in the interferon signaling pathway. IRF-9 is widely expressed in various tissues where it functions as part of the immune response to pathogens. Its expression can be induced by interferons signaling molecules involved in antiviral defense.
Biological function summary

IRF-9 participates in the assembly of the transcription factor complex ISGF3 alongside STAT1 and STAT2. This complex translocates into the nucleus to initiate the transcription of interferon-stimulated genes that promote antiviral states. IRF-9 through this functional role impacts a range of cellular responses including proliferation apoptosis and immune regulation. It affects the temporal and spatial aspects of gene expression in response to interferons.

Pathways

IRF-9 plays a significant role in both the Jak-STAT and interferon signaling pathways. These pathways are essential for the activation of genes involved in immune defense. Through its involvement in these pathways IRF-9 interacts with proteins such as STAT1 and STAT2 creating a bridge between extracellular signals and gene activation. This involvement ensures that cells can respond effectively to viral infections enhancing innate and adaptive immune responses.

IRF-9 has been implicated in autoimmune diseases and certain cancers. Dysfunction in the IRF-9 associated pathways can lead to conditions such as systemic lupus erythematosus where inefficient regulation of immune responses occurs. In cancer altered IRF-9 expression can contribute to uncontrolled cell proliferation. These connections highlight the importance of IRF-9 in maintaining cellular homeostasis and immune integrity. IRF-9's interaction with STAT proteins and interferon pathways highlights its central role in these disease processes.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

製品プロトコール

ターゲットの情報

See full target information IRF9

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com